Genpharmasec Ratios

Genpharmasec Ltd Ratios

The Genpharmasec Ltd Ratios page provides a complete fundamental analysis of Genpharmasec Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Genpharmasec Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Genpharmasec Ltd (NSE: , BSE: 531592) is currently trading at ₹1.18, with a market capitalization of ₹653.39M. As a major player in the Process industries sector and Chemicals: specialty industry, Genpharmasec Ltd remains a key stock for fundamental analysis using Genpharmasec Ltd Ratios.

Genpharmasec Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Genpharmasec Ltd P/E ratio currently stands at 83.63, making it one of the most tracked metrics in Genpharmasec Ltd Ratios.

Historically, the Genpharmasec Ltd P/E ratio has shown strong fluctuations:

• 2024: 83.63
• 2023: 0
• 2022: 76.53
• 2021: 0
• 2020: 173.01

The rising Genpharmasec Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Genpharmasec Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.61.

Historical P/B trend:

• 2024: 1.61
• 2023: 1.85
• 2022: 5.62
• 2021: 9.91

Genpharmasec Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Genpharmasec Ltd P/S ratio currently stands at 3.10, an important part of Genpharmasec Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.10
• 2023: 2.25
• 2022: 3.37
• 2021: 5.57

The rising Genpharmasec Ltd P/S ratio indicates improved revenue valuation by investors.

Genpharmasec Ltd Price to Cash Flow Ratio (P/CF)

The Genpharmasec Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 22.54.

Historical Genpharmasec Ltd Price to Cash Flow Ratio:

• 2024: 22.54
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The rising Genpharmasec Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Genpharmasec Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Genpharmasec Ltd EV currently stands at ₹1.05B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 1.05B
• 2023: 520.19M
• 2022: 862.39M
• 2021: 1.48B

Genpharmasec Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Genpharmasec Ltd EV/EBITDA ratio is currently 350.56, a key metric in Genpharmasec Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 350.56
• 2023: 1130
• 2022: 335.17
• 2021: 0

Stable Genpharmasec Ltd EV/EBITDA indicates balanced valuation.

Genpharmasec Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Genpharmasec Ltd D/E ratio is currently 0.08, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.08
• 2023: 0.06
• 2022: 0.20
• 2021: 0

Genpharmasec Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Genpharmasec Ltd ROE currently stands at 1.94%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 1.94
• 2023: -0.32
• 2022: 7.33
• 2021: -1.16

Declining ROE indicates pressure on profitability.

Genpharmasec Ltd Ratios Analysis Summary

The Genpharmasec Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Genpharmasec Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Genpharmasec Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.